Cooper Companies (The) (COO) Q1 2025 10-Q Quarterly Report

Filed: Mar 7, 2025Period ending Jan 31, 2025
Health Care
Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Mar 7, 2025 for the fiscal period ending Jan 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Cooper Companies (The) Q1 2025 10-Q Analysis

Risk Factors

  • No new or materially changed risk factors reported since 2024 10-K filing
  • Regulatory risk focused on FDA and NMPA approvals for MiSight 1 day myopia management lens in US and China
+3 more insights

Cooper Companies (The) Q1 2025 Quarterly Financials
XBRL

Revenue

$965M

+3.6% YoY

Net Income

$104M

+28.4% YoY

Gross Margin

68.4%

+148bp YoY

Operating Margin

18.9%

+243bp YoY

Net Margin

10.8%

+210bp YoY

EPS (Diluted)

$0.52

+26.8% YoY

Operating Cash Flow

$191M

+55.3% YoY

Source: XBRL data from Cooper Companies (The) Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.